Hims - are earnings going to demolish it or save it?

Hims & Hers Health (HIMS) is scheduled to report its Q4 2025 earnings on Monday, February 23, 2026, after the market closes. Whether the stock will rally is currently a "tug-of-war" between impressive revenue growth and significant regulatory/legal hurdles. Here is the breakdown of the sentiment heading into the report: Analysts are bracing for a "mixed bag" report where the top-line growth looks great, but the bottom line is under pressure. HIMS has a history of beating revenue estimates (6 of the last 8 quarters). If they show that their non-GLP-1 business (hair loss, mental health) is thriving despite the noise, or if they provide strong 2026 guidance, the stock could bounce off its recent lows. Earnings are expected to drop sharply due to aggressive marketing spend and legal costs. Recent sentiment has been "fragile," with the stock hitting 17-month lows just this month. The stock has been extremely volatile lately (down \~50% in the last 30 days) due to two major factors: The GLP-1 "Crackdown": The FDA and big pharma (Novo Nordisk) have increased scrutiny on compounded weight-loss drugs. Since this was a massive growth driver for HIMS, any negative commentary on the legality or future of their "compounded semaglutide" could sink the stock regardless of the numbers. HIMS recently announced a $1.15 billion acquisition of Eucalyptus (an Australian telehealth firm). Investors will be looking for clarity on how this affects their cash flow and if it can offset potential losses in the US weight-loss market. Implied Move: Options traders are pricing in a massive 17% swing (up or down) following the results. This is much higher than their historical average of 5–11%. What do y’all think?